Radicle Science launches several blinded placebo-controlled clinical trials on rare cannabinoids with 10,000 participants in the first half of 2022 on the heels of completing 25 large-scale CBD studies in 2021. SAN DIEGO–(BUSINESS WIRE)–#cannabinoids—Radicle Science, a transformative healthtech B-corp validating health and wellness products for the first time, will launch history’s first large-scale, blinded, placebo-controlled […]

The post Radicle Science Makes History Again With First Large-Scale Clinical Trials on Rare Cannabinoids, Including THCV, CBN, CBG, and CBC appeared first on Fintech News.